secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019130
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q1 net loss narrows to $25.1M; cash runway through Q1 2025
--------------------------------------------------------------------------------

- Net loss of $25.1M ($0.23/sh) vs $28.2M ($0.46/sh) in Q1 2022; revenue rose to $8.8M from $3.3M on Novartis agreement.
- Cash and equivalents $158M; expects runway through Q1 2025.
- Azer-cel: 7 patients in expansion cohort; PBCAR19B: 7 at Dose Level 2; updates expected May 2023.
- In vivo: PBGENE-HBV targeting CTA/IND in 2024; DMD data at ASGCT; R&D Day mid-2023.
- IP: Patent allowed for PCSK9-specific ARCUS nuclease for cardiovascular and gene insertion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023019130/0000950170-23-019130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023019130/dtil-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer